Cart
sales@molnova.com
Home - Products - Metabolic Enzyme/Protease - P450 - Seviteronel

Seviteronel

CAS No. 1610537-15-9

Seviteronel( —— )

Catalog No. M33166 CAS No. 1610537-15-9

Seviteronel (VT-464) is a novel CYP17 cleavage enzyme inhibitor and androgen receptor antagonist used in breast and prostate cancer research.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 259 In Stock
10MG 376 In Stock
25MG 641 In Stock
50MG 892 In Stock
100MG 1190 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Seviteronel
  • Note
    Research use only, not for human use.
  • Brief Description
    Seviteronel (VT-464) is a novel CYP17 cleavage enzyme inhibitor and androgen receptor antagonist used in breast and prostate cancer research.
  • Description
    Seviteronel (VT-464) is a potent CYP17 lyase inhibitor(h-Lyase IC50=69 nM) that demonstrated both exceptional in vitro lyase/hydroxylase selectivity (~10-fold) and oral activity in a hamster model of androgen biosynthesis inhibition.
  • In Vitro
    Seviteronel (VT-464), a non-steroidal small molecule inhibits androgen production without mineralocorticoid excess or cortisol depletion by selective inhibition of CYP17 17,20-lyase. We determined the impact of Seviteronel (VT-464) on tumor growth of a mCRPC xenograft, MDA-PCa-133, in vivo, and on androgen signaling in C4-2B prostate cancer cells in vitro.
  • In Vivo
    The MDA-PCa-133 xenograft is derived from a clinical CRPC bone metastasis. Subcutaneous MDA-PCa-133 tumor expresses PSA, full-length androgen receptor (AR) and AR-V7 isoform. We determined the effect of Seviteronel (VT-464) and AA on MDA-PCa-133 growing in tumor-bearing castrated male mice: randomization into three groups; oral treatment with vehicle only, VT-464, (100 mg/kg bid), or AA (100 mg/kg bid) for 25 days. Both Seviteronel (VT-464)and AA reduced tumor volume (>two fold compared to vehicle; p<0.05). These results indicate that selective Seviteronel (VT-464)CYP17 lyase inhibition is as effective as AA CYP17 inhibition in this model .
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    P450
  • Recptor
    P450 | Androgen Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1610537-15-9
  • Formula Weight
    399.34
  • Molecular Formula
    C18H17F4N3O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : ≥ 50 mg/mL (125.21 mM)
  • SMILES
    CC(C)[C@@](O)(c1c[nH]nn1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Rafferty SW, et al. Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors. Bioorg Med Chem Lett. 2014 Jun 1;24(11):2444-7.?
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • Harman hydrochloride

    Harman hydrochloride can directly induce CYP1A1 gene expression in an AhR-dependent manner and may represent a novel mechanism by which harman promotes mutagenicity, co-mutagenicity and carcinogenicity.

  • EN3356

    EN3356 is an orally available and selective inhibitor of steroidal 17-alpha-hydroxylase/C17,20 cleavage enzyme (CYP17A1 or CYP17), a non-steroidal cleavage enzyme-selective compound with potential anti-androgenic and anti-tumor activity.

  • PF-4981517

    PF-4981517 (CYP3cide) is a efficient, specific and time-dependent inhibitor of cytochrome P4503A4 (CYP3A4). The IC 50 values for CYP3A activity are 0.03 μM,17 μM, and 71 μM for CYP3A4, CYP3A5, and CYP3A7, respectively.

Sign In Join Free